Contribution of TNF receptor 1 to retinal neural cell death induced by elevated glucose

Molecular and Cellular Neuroscience

Volumn 50, Issue 1, 2012, Pages 113-123

  Costa, G N ^a   Vindeirinho, J ^a   Cavadas, C ^a,b   Ambrosio A F ^a,c   Santos, P F ^a,d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Diabetic retinopathy; Neurodegeneration; TNF ; TNFR1

Indexed keywords

CASPASE 3; GLUCOSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL LOSS; CELL VIABILITY; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DIABETIC RETINOPATHY; HYPERGLYCEMIA; IMMUNOREACTIVITY; NEWBORN; NICK END LABELING; NONHUMAN; PATHOGENESIS; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RETINA NERVE CELL;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CASPASE 3; CELL SURVIVAL; CELLS, CULTURED; DIABETIC RETINOPATHY; GLUCOSE; RATS; RATS, WISTAR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RETINAL NEURONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860624256     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2012.04.003     Document Type: Article

References (79)

1. Abu el Asrar A.M., Maimone D., Morse P.H., Gregory S., Reder A.T. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 1992, 114:731-736.
2. Adamis A.P., Berman A.J. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 2008, 30:65-84.
3. Alvarez Y., Chen K., Reynolds A.L., Waghorne N., O'Connor J.J., Kennedy B.N. Predominant cone photoreceptor dysfunction in a hyperglycaemic model of non-proliferative diabetic retinopathy. Dis. Model. Mech. 2010, 3:236-245.
4. Asnaghi V., Gerhardinger C., Hoehn T., Adeboje A., Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003, 52:506-511.
5. Aveleira C.A., Lin C.M., Abcouwer S.F., Ambrosio A.F., Antonetti D.A. TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 2010, 59:2872-2882.
6. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest. 1998, 102:783-791.
7. Barber A.J., Gardner T.W., Abcouwer S.F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:1156-1163.
8. Barker V., Middleton G., Davey F., Davies A.M. TNFalpha contributes to the death of NGF-dependent neurons during development. Nat. Neurosci. 2001, 4:1194-1198.
9. Behl Y., Krothapalli P., Desta T., DiPiazza A., Roy S., Graves D.T. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol. 2008, 172:1411-1418.
10. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
11. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
12. Bolte S., Cordelieres F.P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 2006, 224:213-232.
13. Bradley J.R., Pober J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001, 20:6482-6491.
14. Cho N.C., Poulsen G.L., Ver Hoeve J.N., Nork T.M. Selective loss of S-cones in diabetic retinopathy. Arch. Ophthalmol. 2000, 118:1393-1400.
15. Condorelli F., Sortino M.A., Stella A.M., Canonico P.L. Relative contribution of different receptor subtypes in the response of neuroblastoma cells to tumor necrosis factor-alpha. J. Neurochem. 2000, 75:1172-1179.
16. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
17. El-Remessy A.B., Al-Shabrawey M., Khalifa Y., Tsai N.T., Caldwell R.B., Liou G.I. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am. J. Pathol. 2006, 168:235-244.
18. Feuerstein G.Z., Liu T., Barone F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev. 1994, 6:341-360.
19. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., Eisel U. Neurodegenerative and neuroprotective effects of Tumor Necrosis Factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci. 2002, 22:RC216.
20. Fotin-Mleczek M., Henkler F., Samel D., Reichwein M., Hausser A., Parmryd I., Scheurich P., Schmid J.A., Wajant H. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J. Cell Sci. 2002, 115:2757-2770.
21. Gaucher D., Chiappore J.A., Paques M., Simonutti M., Boitard C., Sahel J.A., Massin P., Picaud S. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007, 47:612-623.
22. Grell M., Wajant H., Zimmermann G., Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:570-575.
23. Gustavsson C., Agardh C.D., Zetterqvist A.V., Nilsson J., Agardh E., Gomez M.F. Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS One 2010, 5:e12699.
24. Hammes H.P., Federoff H.J., Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol. Med. 1995, 1:527-534.
25. Harry G.J., Lefebvre d'Hellencourt C., McPherson C.A., Funk J.A., Aoyama M., Wine R.N. Tumor necrosis factor p55 and p75 receptors are involved in chemical-induced apoptosis of dentate granule neurons. J. Neurochem. 2008, 106:281-298.
26. Hellemans J., Mortier G., De Paepe A., Speleman F., Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007, 8:R19.
27. Heller R.A., Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J. Cell Biol. 1994, 126:5-9.
28. Ibrahim A.S., El-Remessy A.B., Matragoon S., Zhang W., Patel Y., Khan S., Al-Gayyar M.M., El-Shishtawy M.M., Liou G.I. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes 2011, 60:1122-1133.
29. Joussen A.M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Dohmen S., Adamis A.P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002, 16:438-440.
30. Joussen A.M., Doehmen S., Le M.L., Koizumi K., Radetzky S., Krohne T.U., Poulaki V., Semkova I., Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 2009, 15:1418-1428.
31. Kern T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 2007:95103.
32. Kociok N., Radetzky S., Krohne T.U., Gavranic C., Joussen A.M. Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 2006, 47:5057-5065.
33. Koizumi K., Poulaki V., Doehmen S., Welsandt G., Radetzky S., Lappas A., Kociok N., Kirchhof B., Joussen A.M. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest. Ophthalmol. Vis. Sci. 2003, 44:2184-2191.
34. Kontermann R.E., Munkel S., Neumeyer J., Muller D., Branschadel M., Scheurich P., Pfizenmaier K. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J. Immunother. 2008, 31:225-234.
35. Krady J.K., Basu A., Allen C.M., Xu Y., LaNoue K.F., Gardner T.W., Levison S.W. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54:1559-1565.
36. Kuno R., Wang J., Kawanokuchi J., Takeuchi H., Mizuno T., Suzumura A. Autocrine activation of microglia by tumor necrosis factor-alpha. J. Neuroimmunol. 2005, 162:89-96.
37. Kusner L.L., Sarthy V.P., Mohr S. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Muller cells. Invest. Ophthalmol. Vis. Sci. 2004, 45:1553-1561.
38. Limb G.A., Chignell A.H., Green W., LeRoy F., Dumonde D.C. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br. J. Ophthalmol. 1996, 80:168-173.
39. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
40. Luna J.D., Chan C.C., Derevjanik N.L., Mahlow J., Chiu C., Peng B., Tobe T., Campochiaro P.A., Vinores S.A. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J. Neurosci. Res. 1997, 49:268-280.
41. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
42. Manders E.M., Stap J., Brakenhoff G.J., van Driel R., Aten J.A. Dynamics of three-dimensional replication patterns during the S-phase, analysed by double labelling of DNA and confocal microscopy. J. Cell Sci. 1992, 103(Pt 3):857-862.
43. Manders E.M.M., Verbeek F.J., Aten J.A. Measurement of colocalization of objects in dual-color confocal images. J. Microsc. (Oxford) 1993, 169:375-382.
44. Martin P.M., Roon P., Van Ells T.K., Ganapathy V., Smith S.B. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest. Ophthalmol. Vis. Sci. 2004, 45:3330-3336.
45. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., Mansfield E., Gadina M., Karenko L., Pettersson T., McCarthy J., Frucht D.M., Aringer M., Torosyan Y., Teppo A.M., Wilson M., Karaarslan H.M., Wan Y., Todd I., Wood G., Schlimgen R., Kumarajeewa T.R., Cooper S.M., Vella J.P., Amos C.I., Mulley J., Quane K.A., Molloy M.G., Ranki A., Powell R.J., Hitman G.A., O'Shea J.J., Kastner D.L. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
46. Milla M.E., Leesnitzer M.A., Moss M.L., Clay W.C., Carter H.L., Miller A.B., Su J.L., Lambert M.H., Willard D.H., Sheeley D.M., Kost T.A., Burkhart W., Moyer M., Blackburn R.K., Pahel G.L., Mitchell J.L., Hoffman C.R., Becherer J.D. Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE). J. Biol. Chem. 1999, 274:30563-30570.
47. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., Madani H., Widmer M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 1993, 151:1548-1561.
48. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
49. Moss M.L., Jin S.L., Becherer J.D., Bickett D.M., Burkhart W., Chen W.J., Hassler D., Leesnitzer M.T., McGeehan G., Milla M., Moyer M., Rocque W., Seaton T., Schoenen F., Warner J., Willard D. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J. Neuroimmunol. 1997, 72:127-129.
50. Mosselmans R., Hepburn A., Dumont J.E., Fiers W., Galand P. Endocytic pathway of recombinant murine tumor necrosis factor in L-929 cells. J. Immunol. 1988, 141:3096-3100.
51. Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
52. Park S.H., Park J.W., Park S.J., Kim K.Y., Chung J.W., Chun M.H., Oh S.J. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 2003, 46:1260-1268.
53. Park J.S., Woo M.S., Kim D.H., Hyun J.W., Kim W.K., Lee J.C., Kim H.S. Anti-inflammatory mechanisms of isoflavone metabolites in lipopolysaccharide-stimulated microglial cells. J. Pharmacol. Exp. Ther. 2007, 320:1237-1245.
54. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med. 1990, 172:599-607.
55. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11294-11298.
56. Reddy P., Slack J.L., Davis R., Cerretti D.P., Kozlosky C.J., Blanton R.A., Shows D., Peschon J.J., Black R.A. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J. Biol. Chem. 2000, 275:14608-14614.
57. Reddy A.B., Ramana K.V., Srivastava S., Bhatnagar A., Srivastava S.K. Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells. Endocrinology 2009, 150:63-74.
58. Rungger-Brandle E., Dosso A.A., Leuenberger P.M. Glial reactivity, an early feature of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2000, 41:1971-1980.
59. Santiago A.R., Pereira T.S., Garrido M.J., Cristovao A.J., Santos P.F., Ambrosio A.F. High glucose and diabetes increase the release of [3H]-D-aspartate in retinal cell cultures and in rat retinas. Neurochem. Int. 2006, 48:453-458.
60. Santiago A.R., Cristovao A.J., Santos P.F., Carvalho C.M., Ambrosio A.F. High glucose induces caspase-independent cell death in retinal neural cells. Neurobiol. Dis. 2007, 25:464-472.
61. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., Heinrich M., Merkel O., Ehrenschwender M., Adam D., Mentlein R., Kabelitz D., Schutze S. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004, 21:415-428.
62. Sedel F., Bechade C., Vyas S., Triller A. Macrophage-derived tumor necrosis factor alpha, an early developmental signal for motoneuron death. J. Neurosci. 2004, 24:2236-2246.
63. Sfikakis P.P., Markomichelakis N., Theodossiadis G.P., Grigoropoulos V., Katsilambros N., Theodossiadis P.G. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005, 28:445-447.
64. Shibata H., Yoshioka Y., Ohkawa A., Abe Y., Nomura T., Mukai Y., Nakagawa S., Taniai M., Ohta T., Mayumi T., Kamada H., Tsunoda S., Tsutsumi Y. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine 2008, 44:229-233.
65. Solomon K.A., Pesti N., Wu G., Newton R.C. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J. Immunol. 1999, 163:4105-4108.
66. Sone H., Kawakami Y., Okuda Y., Sekine Y., Honmura S., Matsuo K., Segawa T., Suzuki H., Yamashita K. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997, 40:726-730.
67. Takeuchi H., Jin S., Wang J., Zhang G., Kawanokuchi J., Kuno R., Sonobe Y., Mizuno T., Suzumura A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 2006, 281:21362-21368.
68. Tartaglia L.A., Ayres T.M., Wong G.H., Goeddel D.V. A novel domain within the 55kd TNF receptor signals cell death. Cell 1993, 74:845-853.
69. Taylor D.L., Jones F., Kubota E.S., Pocock J.M. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J. Neurosci. 2005, 25:2952-2964.
70. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008, 117:244-279.
71. Tzekov R., Arden G.B. The electroretinogram in diabetic retinopathy. Surv. Ophthalmol. 1999, 44:53-60.
72. Veroni C., Gabriele L., Canini I., Castiello L., Coccia E., Remoli M.E., Columba-Cabezas S., Arico E., Aloisi F., Agresti C. Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Mol. Cell. Neurosci. 2010, 45:234-244.
73. Waetzig G.H., Rosenstiel P., Arlt A., Till A., Brautigam K., Schafer H., Rose-John S., Seegert D., Schreiber S. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J. 2005, 19:91-93.
74. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003, 10:45-65.
75. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999, 17:331-367.
76. Weskamp G., Schlondorff J., Lum L., Becherer J.D., Kim T.W., Saftig P., Hartmann D., Murphy G., Blobel C.P. Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J. Biol. Chem. 2004, 279:4241-4249.
77. Xanthoulea S., Pasparakis M., Kousteni S., Brakebusch C., Wallach D., Bauer J., Lassmann H., Kollias G. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. 2004, 200:367-376.
78. Yang L., Lindholm K., Konishi Y., Li R., Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J. Neurosci. 2002, 22:3025-3032.
79. Yuuki T., Kanda T., Kimura Y., Kotajima N., Tamura J., Kobayashi I., Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J. Diabetes Complications 2001, 15:257-259.